Treatment Intensification with either fludarabine, AraC, G-CSF and Idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients with AML: Results from the NCRI AML18 trial
Russell, N. H. Thomas, A. Hills, R. K. Thomas, I. Gilkes, A. Almuina, N. M. Burns, S. Marsh, L. Vyas, P. Metzner, M.
Russell, N. H.
Thomas, A.
Hills, R. K.
Thomas, I.
Gilkes, A.
Almuina, N. M.
Burns, S.
Marsh, L.
Vyas, P.
Metzner, M.
Citations
Altmetric:
Abstract
PURPOSE: To evaluate the survival benefit of chemotherapy intensification in older patients with AML who have not achieved a measurable residual disease (MRD)-negative remission. METHODS: Five hundred twenty-three patients with AML (median age, 67 years; range, 51-79) without a flow cytometric MRD-negative remission response after a first course of daunorubicin and AraC (DA; including 165 not in remission) were randomly assigned between up to two further courses of DA or intensified chemotherapy-either fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC). RESULTS: Overall survival (OS) was not improved in the intensification arms (DAC v DA: hazard ratio [HR], 0.74 [95% CI, 0.55 to 1.01]; P = .054; FLAG-Ida v DA: HR, 0.86 [95% CI, 0.66 to 1.12]; P = .270); OS at 3 years was 34%, 46%, and 42% for DA, DAC, and FLAG-Ida, respectively. Early deaths and other adverse events were more frequent with FLAG-Ida (9% day 60 deaths v 4% after DA or DAC; P = .032). Of patients entering random assignment, 131 had MRD unknown status. In this subgroup of patients lacking evidence of residual leukemia by flow cytometry, there was no detectable survival advantage from intensification. A planned sensitivity analysis excluding these patients demonstrated a survival benefit for both DAC (HR, 0.66 [95% CI, 0.46 to 0.93]; P = .018) and FLAG-Ida (HR, 0.72 [95% CI, 0.53 to 0.98]; P = .035); OS at 3 years was 30%, 46%, and 46% for DA, DAC, and FLAG-Ida, respectively. There was a concordant reduction in relapse (DAC v DA: HR, 0.66 [95% CI, 0.45 to 0.98]; P = .039; FLAG-Ida v DA: HR, 0.70 [95% CI, 0.49 to 0.99]; P = .042). DAC benefit was maintained when survival was censored for transplant (P = .042). CONCLUSION: In this study of older patients with AML considered fit and with evidence of residual disease after first induction, chemotherapy intensification improved survival. DAC intensification was better tolerated than FLAG-Ida.
Description
Date
2024
Publisher
Collections
Keywords
Type
Article
Citation
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, et al. Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Nov 18:JCO2400259. PubMed PMID: 39556780. Epub 2024/11/18 22:18. eng.